Treatment-Resistant Depression: What to Do When Antidepressants Don't Work
- Sophroneo Psychiatry
- Jul 7
- 12 min read
Treatment-resistant depression does not mean depression is untreatable. It usually means that depressive symptoms have not improved enough after appropriate treatment attempts and that the diagnosis, prior treatments, and next-step options need a more detailed review.
That review matters because there is no single treatment-resistant depression treatment that works for everyone.
Possible next steps may include adjusting the medication strategy, adding another medication, changing psychotherapy, considering transcranial magnetic stimulation, or TMS, discussing electroconvulsive therapy, or ECT, or evaluating whether Spravato esketamine is appropriate.
The National Institute of Mental Health's depression overview describes depression treatment as including medication, psychotherapy, and brain stimulation therapies, while noting that researchers continue to study options for people who do not improve after multiple treatments.
The goal is not to rush through every option.
The goal is to understand why previous treatment did not help enough and what a reasonable next step looks like for your specific clinical history.
What is treatment-resistant depression?
Treatment-resistant depression, often shortened to TRD, commonly refers to major depressive disorder that has not improved enough after multiple appropriate antidepressant treatment trials.
You may often see TRD defined as an inadequate response to at least two antidepressant trials at an adequate dose and duration during the current depressive episode. However, definitions can vary between clinical studies, treatment guidelines, insurers, and specific treatment programs.
That is why the words adequate treatment trial matter.
A clinician may review:
Which antidepressants were tried
The doses used
How long each medication was taken
Whether side effects limited treatment
Whether doses could be adjusted safely
Whether medication was taken consistently
Whether symptoms improved partially
Whether the original diagnosis still fits
Whether another mental or physical health condition is affecting treatment
Someone who stopped medication because of intolerable side effects has a different treatment history from someone who completed an appropriate trial with almost no clinical improvement.
Both situations are important.
They are not necessarily the same type of treatment failure.
If you are unsure how your previous treatments fit together, reviewing your history as part of depression treatment planning may help clarify what has already been tried and what questions remain.
Could treatment-resistant depression actually need reassessment?
Yes. Before assuming depression is biologically resistant to every treatment, clinicians may need to reassess the diagnosis, medication history, medical factors, and conditions occurring alongside depression.
This is sometimes discussed as pseudo-resistance, although the term should not be used to dismiss a patient's suffering.
It simply means there may be a correctable reason why treatment has not worked as expected.
Examples include:
Possible issue | Why it matters |
Treatment stopped early | The medication may not have had a fair trial |
Side effects prevented an effective dose | Tolerability may have limited treatment |
Medication was taken inconsistently | Response becomes difficult to evaluate |
Bipolar disorder has not been identified | The treatment approach may need to change |
Substance use is affecting mood | Symptoms and treatment response may be altered |
Severe insomnia is continuing | Sleep disruption may worsen depressive symptoms |
Trauma or PTSD symptoms are prominent | Depression treatment alone may not address the full picture |
A medical condition contributes to symptoms | Physical health evaluation may be needed |
Medication interactions are present | Treatment tolerability or effectiveness may be affected |
None of this means depression is the patient's fault.
It means a careful diagnosis and treatment review can be just as important as choosing the next medication.
What did the STAR*D study teach us?
The STAR*D study showed that not reaching remission with the first antidepressant is common and that structured next-step treatment matters.
STAR*D, short for Sequenced Treatment Alternatives to Relieve Depression, enrolled more than 4,000 outpatients with major depressive disorder and followed a series of medication treatment steps. Participants who did not become symptom-free could proceed to additional treatment levels.
At the first treatment level, about one-third of evaluable participants reached remission. The study also emphasized measurement-based care, including regular symptom and side-effect tracking rather than relying only on general impressions.
The lesson should not be simplified into “keep trying medications until something works.”
A better lesson is:
One unsuccessful antidepressant treatment does not settle the entire treatment plan.
After an unsuccessful trial, clinicians may need to:
Recheck the diagnosis.
Measure symptoms and side effects.
Review whether the trial was adequate.
Decide whether to switch, augment, or change the treatment approach.
Consider non-medication options when clinically appropriate.
The probability of remission can become lower after repeated unsuccessful treatment steps, so careful decision-making becomes more important, not less.
What are the main treatment-resistant depression treatment options?
Treatment-resistant depression treatment options include medication changes, augmentation strategies, psychotherapy, TMS, ECT, Spravato esketamine, and, in some settings, off-label ketamine treatment.
These options are not interchangeable.
Review and optimize the current treatment plan
The first step is often a detailed review of what has already been tried.
A clinician may examine:
Medication names
Highest tolerated doses
Treatment duration
Side effects
Partial benefits
Reasons for stopping
Therapy history
Previous diagnoses
Sleep
Anxiety
Trauma symptoms
Substance use
Medical conditions
This can prevent unnecessary repetition.
For example, “I tried three antidepressants” does not tell the whole story if two were stopped quickly because of side effects and the third produced partial improvement.
A medication and behavioral health treatment review can help organize previous treatment attempts before the next step is selected.
Switch antidepressant strategies
A clinician may consider switching to another antidepressant when the current medication has not provided enough benefit or is difficult to tolerate.
That might involve a medication from the same broad class or a medication that affects different neurotransmitter systems.
Later-line medication strategies may also include antidepressants that require more specialized prescribing knowledge or monitoring.
The decision depends on factors such as:
Previous response
Side effects
Current symptoms
Other diagnoses
Medical conditions
Medication interactions
Patient preferences
Do not change medication without guidance from your prescriber.
Add an augmentation medication
Augmentation means adding another treatment to an antidepressant rather than replacing the antidepressant immediately.
Depending on the patient's history, a licensed prescriber may discuss options such as:
Certain atypical antipsychotic medications
Lithium
Thyroid hormone in selected situations
Other medication strategies supported by the person's diagnosis and treatment history
Each option has different monitoring needs and possible side effects.
Lithium, for example, requires careful clinical and laboratory monitoring. Some atypical antipsychotic medications may affect weight, movement, or metabolic health.
The point is not that these medications are appropriate for everyone.
The point is that “antidepressants didn't work” does not automatically mean medication-based treatment has reached the end of the road.
Add or change psychotherapy
Psychotherapy can still matter in treatment-resistant depression, even when someone has already tried therapy.
The question is not only, “Have you been to therapy?”
A more useful set of questions is:
What type of therapy did you receive?
What symptoms was it targeting?
Was trauma part of the clinical picture?
Was the therapy structured?
How long did treatment continue?
Were attendance or access barriers present?
Did depression make it difficult to complete therapy work?
Different patients may need different approaches.
Therapy may also remain important alongside medication, TMS, Spravato, or other advanced treatments. It can help address coping patterns, relationships, trauma, stress, functioning, and the practical work of rebuilding daily life.
Is TMS used for treatment-resistant depression?
Yes. TMS is a noninvasive brain stimulation treatment used for depression, particularly when standard treatment has not helped enough.
Transcranial magnetic stimulation uses magnetic pulses to influence activity in targeted brain regions. It does not require general anesthesia and does not intentionally produce a seizure.
The NIMH guide to brain stimulation therapies describes TMS as a noninvasive procedure and distinguishes it from ECT. NIMH also describes brain stimulation therapies as options that may be considered when other treatments have not been effective.
TMS treatment usually involves repeated outpatient sessions.
Possible considerations include:
Treatment schedule
Transportation and work commitments
Headache or scalp discomfort
Previous treatment history
Seizure risk
Implanted metal or medical devices
How progress will be measured
Patients considering this option can review NeuroStar TMS for major depression and discuss whether a TMS evaluation fits their history.
Side effects, benefits, and treatment fit can vary.
When is ECT considered for treatment-resistant depression?
ECT may be considered for severe treatment-resistant depression or situations in which a rapid clinical response is especially important.
Electroconvulsive therapy uses a controlled electrical current to induce seizure activity while the patient is under general anesthesia and receives a muscle relaxant.
Modern ECT is not the same as historical or fictional portrayals of “shock treatment.”
NIMH states that ECT may be considered for severe treatment-resistant depression and when rapid response is needed because of life-threatening circumstances, such as catatonia, severe suicidality, or malnutrition. Memory effects are an important concern and should be discussed as part of informed decision-making.
ECT is not automatically the “last possible treatment.”
It is a distinct medical treatment whose potential benefits, anesthesia requirements, cognitive effects, urgency, and suitability need individual review.
Is Spravato used for treatment-resistant depression?
Yes. Spravato, the brand name for intranasal esketamine, is FDA-approved for treatment-resistant depression in adults.
The current FDA Spravato prescribing information lists treatment-resistant depression in adults as an indication, either as monotherapy or with an oral antidepressant. It also lists depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior when used with an oral antidepressant.
An important limitation applies to the second indication. The FDA label states that Spravato has not been demonstrated to prevent suicide or independently reduce suicidal ideation or behavior, and treatment does not remove the need for hospitalization when clinically warranted.
For mental health emergencies, please call 911.
Spravato is not taken home like a typical daily antidepressant.
Patients administer the nasal spray under direct healthcare supervision and are monitored for at least two hours because of risks including sedation, dissociation, respiratory depression, abuse, and misuse.
Patients researching this option can review Spravato esketamine treatment information before discussing eligibility with a licensed clinician.
Where does ketamine fit in treatment-resistant depression?
Ketamine has an important research and clinical history in difficult-to-treat depression, but ketamine and Spravato should not be treated as identical products.
Spravato contains esketamine and has specific FDA-approved depression indications.
Intravenous racemic ketamine is used by some clinicians for depression off-label. Off-label means the medication is being used for a condition or in a manner that is not specifically included in its FDA-approved labeling.
The FDA's warning about compounded ketamine for psychiatric disorders emphasizes that compounded ketamine products are not FDA-approved for psychiatric disorders and raises concerns about sedation, dissociation, blood pressure changes, respiratory depression, abuse, and other safety risks when treatment occurs without appropriate monitoring.
Patients should ask exactly which product is being offered:
Spravato esketamine nasal spray
IV racemic ketamine
Compounded ketamine
Another formulation
The approval status, evidence, dosing process, monitoring, and insurance pathway can differ.
How do TMS, Spravato, ECT, and medication strategies compare?
The treatments differ in how they are delivered, how quickly they may act, and what clinical situations may lead a clinician to discuss them.
Treatment option | Basic approach | Important practical consideration |
Medication switch | Try a different antidepressant strategy | Benefit and side effects may take time to assess |
Medication augmentation | Add another treatment to the existing plan | Monitoring depends on the medication |
Psychotherapy | Address thoughts, behaviors, trauma, coping, and functioning | Therapy type and treatment target matter |
TMS | Magnetic brain stimulation | Repeated outpatient sessions are usually required |
ECT | Controlled electrical stimulation under anesthesia | Anesthesia and memory-related effects require discussion |
Spravato | Supervised esketamine nasal spray | At least two hours of post-dose monitoring |
IV ketamine | Off-label ketamine infusion for depression | Approval, monitoring, evidence, and coverage differ from Spravato |
The best question is usually not:
“Which treatment is strongest?”
A better question is:
“Which treatment fits my diagnosis, severity, prior treatment response, safety needs, and practical situation?”
Decision-support table: What should you ask about next?
Use this table to organize a clinical conversation. It is not a diagnosis or treatment recommendation.
Your situation | Useful question | Option that may be discussed |
One antidepressant has not helped enough | Was my trial adequate, and should we reassess before calling this TRD? | Medication review |
Two or more appropriate treatments have not helped enough | What TRD options fit my history? | Switch, augmentation, TMS, Spravato, or other care |
Medication helped partly | Should we build on the partial response? | Augmentation or combined treatment |
Side effects keep ending medication trials | Are non-drug options worth discussing? | TMS or psychotherapy |
Depression is severe and a rapid response is medically important | What level of care is appropriate? | Urgent assessment, ECT, or other intensive care depending on the situation |
I am comparing Spravato and TMS | How do the logistics, risks, and evidence differ for me? | TMS or Spravato evaluation |
I have trauma, anxiety, or sleep problems too | Are we treating the full clinical picture? | Therapy and broader care planning |
I have tried many treatments but cannot remember details | Can we reconstruct my treatment history? | Psychiatric and medication review |
Troubleshooting: Why might depression still not be improving?
When treatment is not working, the next step should be thoughtful troubleshooting, not self-blame.
Problem | What may need review |
“Every medication stops because of side effects.” | Dose, medication choice, interactions, and tolerability |
“I felt a little better, but not well.” | Partial response and possible augmentation |
“Therapy didn't help.” | Therapy type, treatment target, duration, and fit |
“I keep being given similar medications.” | Whether a different strategy or mechanism should be discussed |
“No one tracks my symptoms.” | Measurement-based care and functional goals |
“My sleep is terrible.” | Insomnia, sleep disorders, medication effects, and mood |
“My mood changes are more extreme than depression.” | Whether the diagnosis needs reassessment |
“I use alcohol or substances to cope.” | How substance use may be affecting symptoms and safety |
“I have stopped believing anything can work.” | A structured review of what has actually been tried |
Before an appointment, consider writing down:
Every psychiatric medication you remember taking.
Why each medication was stopped.
Any treatment that helped even a little.
The therapies you have tried.
Sleep, trauma, anxiety, and substance-use concerns.
Previous TMS, ketamine, Spravato, or hospital treatment.
What “meaningful improvement” would look like in daily life.
That history can make the next conversation more useful.
How Sophroneo fits
Sophroneo Behavioral Health & TMS can help patients consider treatment-resistant depression within a broader mental health care plan.
How Sophroneo may fit:
Psychiatric evaluations, medication management, and counseling are available for children, adolescents, adults, and families.
Therapy options include CBT, culturally sensitive counseling, solution-focused therapy, motivational interviewing, family therapy, and group therapy.
NeuroStar TMS is available as a non-drug therapy for major depressive disorder when antidepressants have not helped enough.
Spravato esketamine therapy is available for treatment-resistant depression and is administered in clinic with safety monitoring.
Telepsychiatry is available for appropriate visits.
Sophroneo participates in most major insurance plans and accepts private pay. Coverage can vary. Confirm benefits with Sophroneo or your insurance provider.
Sophroneo provides care in Powder Springs/Austell and Stone Mountain. The phone number is 770-999-9495.
Assumptions and limitations
This article assumes the reader is researching treatment-resistant depression in the context of major depressive disorder. It does not diagnose TRD or determine whether any particular treatment is appropriate.
Important limitations:
Definitions of treatment-resistant depression can vary.
Not every unsuccessful medication trial has the same clinical meaning.
Medication augmentation options have different risks and monitoring requirements.
TMS does not work for everyone.
Spravato does not work for everyone and requires supervised administration.
ECT has important anesthesia and cognitive considerations.
IV ketamine for depression is different from FDA-approved Spravato.
Therapy remains relevant for many patients but should be matched to symptoms and clinical needs.
Side effects, benefits, and treatment fit can vary.
A licensed clinician can help determine what is appropriate.
Frequently Asked Questions
How many antidepressants have to fail before depression is treatment-resistant?
A commonly used definition involves inadequate response to at least two appropriate antidepressant trials. However, definitions can differ between studies, guidelines, insurers, and treatment programs.
A clinician should review the dose, duration, adherence, tolerability, and response to each treatment before applying a TRD label.
Does treatment-resistant depression mean I will never recover?
No. Treatment-resistant does not mean untreatable.
It describes a difficult treatment history. It may lead clinicians to reassess the diagnosis and discuss different medication strategies, therapy, TMS, Spravato, ECT, or other appropriate options.
What should I do when antidepressants don't work?
The first step is usually to review what was tried and why it did not help enough.
Ask whether previous treatment trials were adequate, whether there was partial improvement, whether side effects limited treatment, whether the diagnosis needs reassessment, and which next-step options fit your situation.
Is TMS used for treatment-resistant depression?
TMS is used in depression care, particularly when standard treatment has not helped enough.
It is a noninvasive brain stimulation treatment that uses magnetic pulses and usually involves repeated outpatient sessions. A clinician should review treatment history and safety considerations before recommending TMS.
Is Spravato used for treatment-resistant depression?
Yes. Spravato is FDA-approved for treatment-resistant depression in adults, either as monotherapy or with an oral antidepressant.
It is administered under direct healthcare supervision and requires post-dose monitoring for at least two hours.
Is ketamine the same as Spravato?
No.
Spravato contains esketamine and has specific FDA-approved depression indications. IV racemic ketamine is a different treatment and is generally used off-label when provided for depression.
When is ECT considered?
ECT may be considered for severe treatment-resistant depression or when a rapid response is needed because the clinical situation is serious or life-threatening.
A clinician should discuss anesthesia, memory effects, potential benefits, and individual treatment fit.
Can therapy still help after medications fail?
Yes. Medication non-response does not automatically mean psychotherapy cannot help.
The type of therapy, treatment target, duration, trauma history, attendance, and ability to engage with therapy all matter. Therapy may also be used alongside TMS, medication management, or other depression treatments.
Can I stop my antidepressant before trying TMS or Spravato?
Do not stop, reduce, or change antidepressant medication without guidance from your prescriber.
Whether medication continues during TMS or Spravato treatment depends on the treatment plan, the specific indication, your medical history, and clinician judgment.
If antidepressants have not helped enough and you want a clearer review of what you have tried and what options remain, consider scheduling an appointment to discuss treatment-resistant depression, medication management, therapy, NeuroStar TMS, Spravato, or other appropriate next steps.